# Inhaled bispecific single-domain antibody BM219 for mild-to-moderate COVID-19: a double-blind, randomized, placebo-controlled phase 2 trial

**Authors:** Yanling Wu, Yuan Li, Ping Zhang, Siwei Guo, Fang Yuan, Vivian Liu, Ting Yu, Feng Lin, Nan Yang, Chao Tu, Hongzhou Lu, Tianlei Ying, Xin Li

PMC · DOI: 10.1038/s41421-025-00813-0 · Cell Discovery · 2025-07-17

## Full-text entities

- **Diseases:** COVID-19 (MESH:D000086382)
- **Chemicals:** BM219 (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12271308/full.md

## Figures

1 figure with captions in the complete paper: https://tomesphere.com/paper/PMC12271308/full.md

## References

2 references — full list in the complete paper: https://tomesphere.com/paper/PMC12271308/full.md

---
Source: https://tomesphere.com/paper/PMC12271308